Literature DB >> 11241283

Cloning and characterization of a novel mouse myeloid DAP12-associated receptor family.

M R Daws1, L L Lanier, W E Seaman, J C Ryan.   

Abstract

The presence of a negatively charged residue in the transmembrane domain of DAP12 precludes its cell surface expression in the absence of a partner receptor containing a positive charge in its transmembrane domain. We utilized this property of DAP12 to screen a BALB / c macrophage cDNA library for novel molecules that induce cell surface expression of DAP12. By this method, we cloned a cell surface receptor with a single Ig (V) domain, a transmembrane lysine residue, and a short cytoplasmic domain. By homology screening of BALB / c macrophage libraries, we identified a second cDNA for a highly homologous receptor. These receptors appear to be the mouse orthologues of a recently identified human cDNA, TREM-2, so we have designated the receptors as mouse TREM-2a and TREM-2b. By Northern blotting, transcripts for TREM-2 were found in each of three macrophage cell lines but not in a variety of other hematopoietic cell lines. We further demonstrate that TREM-2a is associated with endogenous DAP12 in macrophage cells, and cross-linking of TREM-2a on the surface of macrophages leads to the release of nitric oxide. Our studies define TREM-2 as a receptor family in mouse macrophages and demonstrate the capacity of these receptors to activate macrophage function through DAP12.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11241283     DOI: 10.1002/1521-4141(200103)31:3<783::aid-immu783>3.0.co;2-u

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  66 in total

Review 1.  Triggering receptor expressed on myeloid cells receptor family modulators: a patent review.

Authors:  Christopher J Pelham; Amit N Pandya; Devendra K Agrawal
Journal:  Expert Opin Ther Pat       Date:  2014-11-01       Impact factor: 6.674

Review 2.  Microglial activation in stroke: therapeutic targets.

Authors:  Midori A Yenari; Tiina M Kauppinen; Raymond A Swanson
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

Review 3.  The role of the microglia in acute CNS injury.

Authors:  Masahito Kawabori; Midori A Yenari
Journal:  Metab Brain Dis       Date:  2014-03-29       Impact factor: 3.584

Review 4.  CNS immune privilege: hiding in plain sight.

Authors:  Monica J Carson; Jonathan M Doose; Benoit Melchior; Christoph D Schmid; Corinne C Ploix
Journal:  Immunol Rev       Date:  2006-10       Impact factor: 12.988

5.  Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12.

Authors:  Jessica A Hamerman; Nadia K Tchao; Clifford A Lowell; Lewis L Lanier
Journal:  Nat Immunol       Date:  2005-05-15       Impact factor: 25.606

Review 6.  Microglia and the control of autoreactive T cell responses.

Authors:  Benoit Melchior; Shweta S Puntambekar; Monica J Carson
Journal:  Neurochem Int       Date:  2006-06-08       Impact factor: 3.921

7.  Modulation of the triggering receptor expressed on the myeloid cell type 1 pathway in murine septic shock.

Authors:  Sébastien Gibot; Cecilia Buonsanti; Frédéric Massin; Michele Romano; Marie-Nathalie Kolopp-Sarda; Fabio Benigni; Gilbert C Faure; Marie-Christine Béné; Paola Panina-Bordignon; Nadia Passini; Bruno Lévy
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

Review 8.  TREM2 variants: new keys to decipher Alzheimer disease pathogenesis.

Authors:  Marco Colonna; Yaming Wang
Journal:  Nat Rev Neurosci       Date:  2016-02-25       Impact factor: 34.870

Review 9.  The role of immune dysfunction in the pathophysiology of autism.

Authors:  Charity Onore; Milo Careaga; Paul Ashwood
Journal:  Brain Behav Immun       Date:  2011-08-28       Impact factor: 7.217

10.  TREM-2 binds to lipooligosaccharides of Neisseria gonorrhoeae and is expressed on reproductive tract epithelial cells.

Authors:  D N Quan; M D Cooper; J L Potter; M H Roberts; H Cheng; G A Jarvis
Journal:  Mucosal Immunol       Date:  2008-03-05       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.